Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über SAREPTA THERAPEUTICS, INC.
11.01.Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional ..
10.01.Sarepta Reports Positive Data From Clinical Trial for Duchenne Muscular Dystrophy Treat..
10.01.SAREPTA THERAPEUTICS : J.P. Morgan 2022 Presentation
10.01.SAREPTA THERAPEUTICS : rsquo; Gene Therapy SRP-9001 Shows Statistically Significant Functi..
10.01.SAREPTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD ..
10.01.Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional ..
10.01.Sarepta Therapeutics, Inc. Announces Topline Results from Part 2 of Study SRP-9001-102
06.01.Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
01.01.Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021JPMorgan moves healthcare conference online amid Omicron concerns
2021Sarepta scraps plan to attend major healthcare conference next month
2021Sarepta Therapeutics scraps plan to attend in-person healthcare conference next month
2021Certain Restricted Stock Units of Sarepta Therapeutics, Inc. are subject to a Lock-Up A..
2021Certain Common Stock of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement E..
2021Certain Stock Options of Sarepta Therapeutics, Inc. are subject to a Lock-Up Agreement ..
2021Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021INSIDER BUY : Sarepta Therapeutics
2021SAREPTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
2021Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Developmen..
2021Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
2021Sarepta Therapeutics Names Louise Rodino-Klapac as Head of Research and Development
2021Sarepta Therapeutics Appoints Stephen L. Mayo to Its Board of Directors
2021PATIENT REGISTRIES : A catalyst for developing new therapies for rare diseases
2021Sarepta Therapeutics Posts Narrower Q3 Loss, Higher Revenue
2021SAREPTA THERAPEUTICS : Q3 Earnings Snapshot
2021Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q3 Revenue $189.4M, vs. Street Est o..
2021Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q3 Loss $-0.19, vs. Street Est of $-..
2021SAREPTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
2021Sarepta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
2021Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporat..
2021Sarepta Therapeutics, Inc. Announces Revenue Guidance for the Year 2021
2021EARNINGS REACTION HISTORY : Sarepta Therapeutics Inc, 70.0% Follow-Through Indicator, 5.6%..
2021Sarepta Therapeutics to Present at Upcoming Investor Conferences
2021Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corpor..
2021SAREPTA THERAPEUTICS : Announces Preliminary Financial Results for the Third Quarter Ended..
2021SAREPTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operat..
2021SAREPTA THERAPEUTICS : Prices Public Offering at $81/Share, Expects $500 Million Gross Pro..
2021Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
2021SAREPTA THERAPEUTICS : Announces Pricing of $500 Million Public Offering of Common Stock
2021Health Care Stocks Edging Higher Ahead of Wednesday Close
2021SAREPTA THERAPEUTICS : Cash Levels Drop From Year-End 2020; Shares Down
2021SAREPTA THERAPEUTICS : Estimates Higher Q3 Product Revenue
2021SAREPTA THERAPEUTICS : Starts $500 Million Common Stock Offering
2021SAREPTA THERAPEUTICS : Announces Preliminary Financial Results for the Third Quar-ter Ende..
2021SAREPTA THERAPEUTICS : Announces Proposed $500,000,000 Public Offering of Common Stock
2021Sarepta Therapeutics, Inc. Reports Preliminary Revenue Guidance for the Third Quarter E..
2021SAREPTA THERAPEUTICS' : Muscular Dystrophy Drug Shows Potential in Late-Stage Trial
2021SAREPTA THERAPEUTICS : ' SRP-9001 Shows Sustained Functional Improvements in Multiple Stud..
2021Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Stud..
2021Les valeurs à suivre aujourd'hui à Paris - Lundi 11 octobre 2021
2021LYSOGENE : A suivre aujourd'hui
2021Les valeurs à suivre lundi 11 octobre 2021 à la Bourse de Paris
2021LYSOGENE : recul de la position de trésorerie
2021CODIAK BIOSCIENCES : Says Sarepta Therapeutics Terminates Research License, Option Agreeme..
2021SAREPTA THERAPEUTICS : Opens Genetic Therapies Center of Excellence in Columbus, Ohio
2021Sarepta Therapeutics, Inc. Opens Genetic Therapies Center of Excellence in Columbus, Oh..
2021SAREPTA THERAPEUTICS : Commences SRP-9001 Study in Duchenne Muscular Dystrophy
2021SAREPTA THERAPEUTICS : Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001,..
2021Sarepta Therapeutics Announces Initiation of EMBARK, Study of SRP-9001, a Gene Therapy ..
2021SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021SAREPTA THERAPEUTICS : to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with D..
2021SAREPTA THERAPEUTICS : to Initiate Part B of Study Into Duchenne Muscular Dystrophy Treatm..
2021SAREPTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
2021Sarepta Therapeutics, Inc. to Initiate Part B of Momentum Study of SRP-5051 in Patients..
2021Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with ..
2021SEROPREVALENCE : What patients should know about pre-existing antibodies to gene therapy
2021SELECTA BIOSCIENCES : Names Kevin Tan Finance Chief
2021SELECTA BIOSCIENCES : Hires Kevin Tan as CFO
2021SAREPTA THERAPEUTICS, INC.(NASDAQGS : SRPT) dropped from FTSE All-World Index
2021SAREPTA THERAPEUTICS : to Showcase Data from its Gene Therapy and RNA Platforms at World M..
2021SAREPTA THERAPEUTICS : EP.096 Peterson et al. Micro-dystrophin gene transfer therapy and T..
2021SAREPTA THERAPEUTICS : EP.149 Iff et al. Delay in DMD prog with eteplirsen longer time to ..
2021SAREPTA THERAPEUTICS : LBP.22 Mercuri et al. Safety tol and PK of etep in pts 6-48 mon wit..
2021SAREPTA THERAPEUTICS : to Present at Upcoming Investor Conferences
1  2  3  4  5  6  7  8  9  10Weiter
Anstehende Termine für SAREPTA THERAPEUTICS, INC.